SEVER Life Sciences to share Lacrifill data at AAO 2026

SEVER Life Sciences B.V. and its U.S. subsidiary Nordic Pharma say they will present and share patient data and patient experience studies for Lacrifill Canalicular Gel, a therapy aimed at ocular surface control, at the American Academy of Ophthalmology (AAO) conference in New Orleans in October 2026. The company notes thousands of practices use Lacrifill and tens of thousands of patients have been treated, highlighting use in cataract and refractive surgery contexts as well as dry eye symptoms. This explainer breaks down what this means, who may be affected, and practical next steps for patients and clinicians.

What is Lacrifill Canalicular Gel and what is changing

Lacrifill Canalicular Gel is described by the company as a novel therapy aimed at regulating the ocular surface, which may help patients who have undergone eye surgery or who have dry eye symptoms. The company says it will share new patient data and patient experience results during the AAO 2026 meeting. This indicates more information will be presented about how well the product works in real-world use and what patients report about their experience.

Key facts about who is involved and what is being shared

The company involved is SEVER Life Sciences B.V. and its U.S. subsidiary Nordic Pharma, Inc., which plan to feature Lacrifill Canalicular Gel at the AAO 2026 conference. The announcement mentions more than 2,200 ophthalmology and optometry practices in the United States using Lacrifill, and more than 130,000 patients having been treated with this therapy. These figures reflect current adoption and usage, not a change in regulatory status. The event is a professional conference, implying the data to be presented is intended for clinicians and researchers rather than the general public.

Who is affected by this development

Patients who have undergone cataract or refractive surgery and patients with dry eye disease using Lacrifill Canalicular Gel may be affected in terms of new data about outcomes and patient experience. Clinicians who treat dry eye or perform eye surgeries could use the new information to guide treatment decisions. The release does not specify any changes to patient eligibility or access outside of ongoing use and reporting at the conference.

Practical next steps for patients and clinicians

For clinicians: review the Lacrifill data and patient experience findings when they are presented at AAO 2026; consider how the data align with current practice and patient-reported outcomes. For patients: continue to follow your clinician’s guidance regarding Lacrifill use; if you are part of a study or receive new information at your clinic, discuss any implications for your treatment plan. There is no indication of immediate changes to availability or coverage based on the announcement.

Limits of the information and questions to ask

The current communication centers on data sharing and patient experience presentations at a conference, with no formal statements about regulatory changes, safety updates, or coverage. Important questions include: What specific outcomes are being measured? How will patient privacy be protected in any data sharing? Will the data include identifiable patient information or be de-identified? When and where will the data be published beyond the conference, if at all?

Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.